Group 1 - The core viewpoint of the article is that Haohai Biological's revenue and net profit have declined in the first half of 2025, indicating challenges in its key business segments, particularly in medical aesthetics and ophthalmology [1][2][3] - The company reported a revenue of 1.304 billion yuan, a year-on-year decrease of 7.12%, and a net profit attributable to shareholders of 211 million yuan, down 10.29% [1][2] - The main product segments, including medical aesthetics, ophthalmology, and orthopedics, all experienced revenue declines, with medical aesthetics generating 575 million yuan, down 9.31%, ophthalmology 368 million yuan, down 18.61%, and orthopedics 227 million yuan, down 2.58% [2][3] Group 2 - The decline in the hyaluronic acid business is attributed to changes in VAT rates affecting sales revenue and weak sales of entry-level products, which have not sustained their market advantage for nearly a decade [3][4] - The company’s high-end products, such as the third-generation and fourth-generation hyaluronic acid series, are performing well, but the overall medical aesthetics business may face negative growth for the first time this year [5][6] - The ophthalmology segment has seen significant revenue drops, particularly in cataract surgery products, which fell by 28.76%, largely due to national medical cost control policies [6][7] Group 3 - The company is actively responding to declining performance by focusing on high-end products and has seen a 73.82% increase in sales of mid-range pre-filled non-spherical products [9][10] - The competitive landscape in the medical aesthetics market is challenging, with several leading companies reporting similar revenue declines, indicating a broader industry adjustment [5][6] - The strategic shift towards mid-to-high-end products is seen as an opportunity, but the company faces challenges in product development and market penetration due to strong competition from imported brands [9][10]
昊海生科营利双降,两大主营业务均下滑